ESGCT is thrilled to announce that ESGCT will continue supporting student members who are presenting authors of an abstract accepted for an oral or a poster presentation. The registration fees for those students will be waived to enable them to attend the congress free of charge if they hold PAID ESGCT student membership at the dates of the congress **
European national society members We are delighted to be holding the congress in collaboration with eight European national gene and cell therapy societies. If you are already a paid up member of your country’s society, you are entitled to free membership of the ESGCT for 2021, enabling you to take advantage of the preferential congress rates for society members. You should have received an email from your national society regarding this arrangement*. Should you wish to remain a member of ESGCT for 2022 onwards, the usual fees will apply. Non ESGCT Members: Membership is available here, and is currently priced at €30 for Students, €60 for Academic, and €180 for Industry. Amongst other benefits, becoming a member gives you considerable savings on your registration rates.
**Student members: ESGCT student members whose abstracts are accepted for an oral or a poster presentation can attend the congress free of charge!
Non-viral genetic therapy strategies for the treatment of ataxia telangiectasia
James Grey received the ESGCT-sponsored prize for best poster presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about his winning presentation here!
Gene therapy for thrombotic thrombocytopaenic purpura
Robyn Bell received the ESGCT-sponsored prize for best oral presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about her winning presentation here!
CRISPR-Cas9 genome editing - molecular scissors a bit too sharp?
Grégoire Cullot received the ESGCT-sponsored prize for best oral presentation at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about his winning presentation here!
Dgkk as a new therapeutic target in the Fmr1-KO murine model of Fragile X
Karima Habbas received the ESGCT-sponsored prize for best poster at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about her winning presentation here!